New flu vaccine with booster additive enters human trials

NCT ID NCT06824519

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new seasonal flu vaccine that includes an adjuvant (ZFA02) to potentially boost the immune response. The trial involves 620 adults aged 18 and older, split into low-dose and high-dose groups, with some receiving a placebo. Researchers will monitor side effects and measure antibody levels to see how well the vaccine works against four flu strains.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Influenza vaccine (split virion, inactivated, quadrivalent) with ZFA02 adjuvant
What this could lead to: If successful, this could lead to a more effective seasonal flu vaccine that provides broader protection against multiple flu strains.
What could go wrong: This is an early-phase trial (phase 1/2) with only 620 participants, so the vaccine may not prove safe or effective in larger populations. Side effects like injection-site reactions or fever are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA, HUMAN

Contacts and locations

Locations

Hebei Province Centers for Disease Control and Prevention
RECRUITING

Shijiazhuang, Hebei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.